Annotation Detail
Information
- Associated Genes
- RET
- Associated Variants
- RET KIF5B-RET
- Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion of KIF5B and RET. The patient was enrolled in a clinical trial with vandetanib and everolimus (NCT01582191) with everolimus used to enhance brain accumulation of vandetanib. After two cycles of therapy a repeat MRI brain showed a decrease in the intracranial disease burden and PET/CT showed systemic response as well.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1622
- Gene URL
- https://civic.genome.wustl.edu/links/genes/42
- Variant URL
- https://civic.genome.wustl.edu/links/variants/273
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Vandetanib,Everolimus
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25982012
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Everolimus | Sensitivity | true |
| Vandetanib | Sensitivity | true |